Prophylactic, single-drug cardioprotection in a comparative, experimental study of doxorubicin-induced cardiomyopathy

BACKGROUND: Cardiomyopathy is a common side effect of doxorubicin (DOX) chemotherapy. Despite intensive research efforts in the field, there is still no evidence available for routine cardioprotective prophylaxis to prevent cardiotoxicity in the majority of oncological patients at low risk of cardio...

Descripción completa

Detalles Bibliográficos
Autores principales: Lódi, Mária, Bánhegyi, Viktor, Bódi, Beáta, Gyöngyösi, Alexandra, Kovács, Árpád, Árokszállási, Anita, Hamdani, Nazha, Fagyas, Miklós, Édes, István, Csanádi, Zoltán, Czuriga, István, Kisvárday, Zoltán, Lekli, István, Bai, Péter, Tóth, Attila, Papp, Zoltán, Czuriga, Dániel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725221/
https://www.ncbi.nlm.nih.gov/pubmed/33298102
http://dx.doi.org/10.1186/s12967-020-02564-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725221/
https://www.ncbi.nlm.nih.gov/pubmed/33298102
http://dx.doi.org/10.1186/s12967-020-02564-w

Ejemplares similares